Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585866 | 1.00 | EPHX1 (0.47) | EPHX1DPP8DPP9DPP7MEN1 | |
| Hydrochloric Acid SCHEMBL4087778 | 0.99 | EPHX1 (0.46) | EPHX1DPP8DPP9DPP7MEN1 | |
| SCHEMBL8341764 | 0.91 | NPY4R (0.47) | EPHX1DPP8DPP9DPP7MEN1 | |
| SCHEMBL27352129 | 0.91 | NPY4R (0.47) | EPHX1DPP8DPP9DPP7MEN1 | |
| Dl-Phenylalanine SCHEMBL20580864 | 0.91 | LTA4H (0.43) | EPHX1LTA4HSLC1A3SLC1A2SLC1A1 | |
| Phenylalanine SCHEMBL18953085 | 0.91 | LTA4H (0.43) | EPHX1LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9490109 | 0.90 | TERT (0.51) | EPHX1DPP8DPP9DPP7MEN1 | |
| SCHEMBL8338954 | 0.87 | NPY4R (0.46) | EPHX1DPP8DPP9DPP7LTA4H | |
| SCHEMBL13437223 | 0.85 | EPHX1 (0.47) | EPHX1MEN1KMT2AMAPTPOLB | |
| SCHEMBL8768680 | 0.85 | LTA4H (0.47) | EPHX1POLBRAB9ASMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250338851-A1 | Boosted IPBC for Wet-State Bacterial Control | TROY TECH II INC (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2025215171-A1 | COMBINATIONS OF PYRIDINE THIOLATE OXIDE COMPOUNDS AND CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR USE IN THE TREATMENT OF LUNG INFECTIONS IN SUBJECTS WITH CYSTIC FIBROSIS | UNIVERSITY OF ZARAGOZA (ES) | 2025-10-16 | — | — | WO | disclosed |
| CN-119889469-A | Screening method and application of campylobacter function-enhanced multiple drug-resistant efflux pump variant RE-CmeABC inhibitor | 河南农业大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-4326942-A1 | BOOSTED IPBC FOR WET-STATE BACTERIAL CONTROL | Troy Technology II, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117599153-A | Gram-negative bacteria antibiotic sensitizer and application thereof | 武汉大学 | 2024-02-27 | — | — | CN | disclosed |
| WO-2022246218-A9 | BOOSTED IPBC FOR WET-STATE BACTERIAL CONTROL | TROY TECHNOLOGY II, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022246218-A1 | BOOSTED IPBC FOR WET-STATE BACTERIAL CONTROL | TROY TECHNOLOGY II, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | EPHX1 1886/4885DPP8 41/4885DPP9 59/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | EPHX1 3404/4885DPP8 40/4885DPP9 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.